Literature DB >> 29532797

Immunotherapy: Immune-modified response criteria - an iterative learning process?

Patrick A Ott1.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29532797     DOI： 10.1038/nrclinonc.2018.36

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  7 in total

Review 1.  iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.

Authors:  Lesley Seymour; Jan Bogaerts; Andrea Perrone; Robert Ford; Lawrence H Schwartz; Sumithra Mandrekar; Nancy U Lin; Saskia Litière; Janet Dancey; Alice Chen; F Stephen Hodi; Patrick Therasse; Otto S Hoekstra; Lalitha K Shankar; Jedd D Wolchok; Marcus Ballinger; Caroline Caramella; Elisabeth G E de Vries
Journal:  Lancet Oncol       Date:  2017-03-02       Impact factor: 41.316

2.  Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions.

Authors:  Mizuki Nishino; Anita Giobbie-Hurder; Michael P Manos; Nancy Bailey; Elizabeth I Buchbinder; Patrick A Ott; Nikhil H Ramaiya; F Stephen Hodi
Journal:  Clin Cancer Res       Date:  2017-06-07       Impact factor: 12.531

3.  Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements.

Authors:  Mizuki Nishino; Anita Giobbie-Hurder; Maria Gargano; Margaret Suda; Nikhil H Ramaiya; F Stephen Hodi
Journal:  Clin Cancer Res       Date:  2013-06-06       Impact factor: 12.531

4.  Reporting results of cancer treatment.

Authors:  A B Miller; B Hoogstraten; M Staquet; A Winkler
Journal:  Cancer       Date:  1981-01-01       Impact factor: 6.860

5.  Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.

Authors:  Jedd D Wolchok; Axel Hoos; Steven O'Day; Jeffrey S Weber; Omid Hamid; Celeste Lebbé; Michele Maio; Michael Binder; Oliver Bohnsack; Geoffrey Nichol; Rachel Humphrey; F Stephen Hodi
Journal:  Clin Cancer Res       Date:  2009-11-24       Impact factor: 12.531

6.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

7.  Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy.

Authors:  F Stephen Hodi; Marcus Ballinger; Benjamin Lyons; Jean-Charles Soria; Mizuki Nishino; Josep Tabernero; Thomas Powles; David Smith; Axel Hoos; Chris McKenna; Ulrich Beyer; Ina Rhee; Gregg Fine; Nathan Winslow; Daniel S Chen; Jedd D Wolchok
Journal:  J Clin Oncol       Date:  2018-01-17       Impact factor: 44.544
  7 in total
  2 in total

1.  Cytokine-induced killer cells co-cultured with non-cell derived targeting peptide-loaded dendritic cells induce a specific antitumor response.

Authors:  Cuijuan Liu; Xueyuan Cui; Dayong Zhou; Chunlin Li; Mengya Zhao; Yaqing Jin; Chen Ding; Yimin Zhu
Journal:  Cancer Biol Ther       Date:  2019-02-19       Impact factor: 4.742

Review 2.  Current progress, challenges and future prospects of diagnostic and therapeutic interventions in Alzheimer's disease.

Authors:  K Rajasekhar; Thimmaiah Govindaraju
Journal:  RSC Adv       Date:  2018-06-29       Impact factor: 4.036
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.